" ..probably the cheapest by value of any advanced Oncology R &...

" ..probably the cheapest by value of any advanced Oncology R & D listing "

It definitely is, no doubt. CDH 17 Trial progressing like the 2 NK-cell trials. Definitely years ahead of ALA.

So why the up to 20x higher MC difference?

ALA gets valued before any results, CHM has to prove the value by delivering first.
ALA gets thrown money at, CHM can't find any.

The obvious reason aren't results, the reason is a failed funding strategy by CHM plus, so far, ZERO interest by big pharma. ALA, according to its value and targeting the CD19 blood cancer space like more than 300 other comps needs to perform " miracles " to justify its value. CHM got a image problem too, the boss.

For patients and investors sake, let's hope Dr Bec can turn the ship back on course. Today's anns shows that at least the CHM crew is working hard.

GLTA